Related Experiment Videos
Evidence for central benzodiazepine receptor heterogeneity from behavior tests
M F Davies1, E S Onaivi, S W Chen
1Molecular Research Institute, Palo Alto, CA 94304.
Pharmacology, Biochemistry, and Behavior
|September 1, 1994
Summary
Behavioral selectivity arises from multiple benzodiazepine receptor subtypes. Different ligands show varied effects on anxiety, activity, and seizures, indicating complex interactions with central benzodiazepine receptors.
Area of Science:
- Neuropharmacology
- Behavioral Neuroscience
Background:
- Benzodiazepines are widely used drugs acting on central nervous system receptors.
- Understanding the specific receptor subtypes targeted by different benzodiazepine ligands is crucial for predicting their behavioral effects.
Purpose of the Study:
- To investigate the behavioral selectivity of four benzodiazepine receptor ligands: flunitrazepam, CGS 9896, zolpidem, and AHR 11797.
- To determine if observed behavioral differences are attributable to interactions with multiple benzodiazepine receptor subtypes.
Main Methods:
- In vivo testing of four benzodiazepine ligands across five endpoints: anticonvulsant activity, anxiety-like behavior (plus-maze test), locomotor activity, food consumption, and hypothermia.
- Administration of Ro15-1788 as an antagonist to confirm receptor involvement.
Main Results:
- All tested compounds induced hypothermia.
- Ligands exhibited differential effects on anxiety-like behavior, locomotor activity, and food consumption.
- Only flunitrazepam demonstrated full protection against pentylenetetrazol-induced seizures.
- Ro15-1788 antagonism confirmed that all observed effects involved central benzodiazepine receptors.
Conclusions:
- The diverse behavioral profiles of the tested benzodiazepine ligands suggest they interact with multiple central benzodiazepine receptor subtypes.
- Behavioral selectivity is a consequence of these complex receptor interactions, rather than a single subtype effect.